Wang H - Search Results

1

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Cohen SJ, et al. Among authors: wang h. J Clin Oncol. 2003 Apr 1;21(7):1301-6. doi: 10.1200/JCO.2003.08.040. J Clin Oncol. 2003. PMID: 12663718 Clinical Trial.

2

Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.

Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. Haas NB, et al. Among authors: wang h. Clin Cancer Res. 2003 Jan;9(1):109-14. Clin Cancer Res. 2003. PMID: 12538458 Clinical Trial.

3

Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas.

Meszoely IM, Lee JS, Watson JC, Meyers M, Wang H, Hoffman JP. Meszoely IM, et al. Among authors: wang h. Am Surg. 2004 Mar;70(3):208-13; discussion 213-4. Am Surg. 2004. PMID: 15055843

4

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR. Rogatko A, et al. Among authors: wang h. Clin Cancer Res. 2004 Jul 15;10(14):4645-51. doi: 10.1158/1078-0432.CCR-03-0535. Clin Cancer Res. 2004. PMID: 15269136

5

Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003.

Meszoely IM, Wang H, Hoffman JP. Meszoely IM, et al. Among authors: wang h. Surg Oncol Clin N Am. 2004 Oct;13(4):685-96, x. doi: 10.1016/j.soc.2004.06.013. Surg Oncol Clin N Am. 2004. PMID: 15350942 Review.

6

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.

Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR. Borghaei H, et al. Among authors: wang h. Cancer. 2004 Nov 1;101(9):2034-41. doi: 10.1002/cncr.20616. Cancer. 2004. PMID: 15455357 Free article. Clinical Trial.

7

Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.

Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Morris GJ, et al. Among authors: wang h. Haematologica. 2004 Dec;89(12):1484-91. Haematologica. 2004. PMID: 15590399 Clinical Trial.

8

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. Carlini LE, et al. Among authors: wang h. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. Clin Cancer Res. 2005. PMID: 15709193 Clinical Trial.

9

Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.

Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Cheng JD, et al. Among authors: wang h. Mol Cancer Ther. 2005 Mar;4(3):351-60. doi: 10.1158/1535-7163.MCT-04-0269. Mol Cancer Ther. 2005. PMID: 15767544

10

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.

Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Berger AC, et al. Among authors: wang h. J Clin Oncol. 2005 Jul 1;23(19):4330-7. doi: 10.1200/JCO.2005.05.017. Epub 2005 Mar 21. J Clin Oncol. 2005. PMID: 15781882 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148,852 results

Search Page

Filters